Page 107 - 《中国药房》2023年20期

WU H B，ZHANG X J，ZHANG Y，et al. Efficacy of Cardiovasc Care，2021，10（9）：1009-1015.
IMRT intensity-modulated radiotherapy combined with [15] FURUKAWA K，NAGANO T，TACHIHARA M，et al.
concurrent TP regimen in the treatment of inoperable Interaction between immunotherapy and antiangiogenic
stage Ⅲ non-small cell lung cancer[J]. Med J West China， therapy for cancer[J]. Molecules，2020，25（17）：3900.
2020，32（9）：1342-1345，1349. [16] AN D，BANERJEE S，LEE J M. Recent advancements of
[ 4 ] HE J Y，HUANG Z R，HAN L Z，et al. Mechanisms and antiangiogenic combination therapies in ovarian cancer[J].
management of 3rd-generation EGFR-TKI resistance in Cancer Treat Rev，2021，98：102224.
advanced non-small cell lung cancer：review[J]. Int J [17] FERRARA R，IMBIMBO M，MALOUF R，et al. Single
Oncol，2021，59（5）：90. or combined immune checkpoint inhibitors compared to
[ 5 ] POGODA L，ZIYLAN F，SMEEING D P J，et al. Bevaci‐ first-line platinum-based chemotherapy with or without
zumab as treatment option for recurrent respiratory papil‐ bevacizumab for people with advanced non-small cell
lomatosis：a systematic review[J]. Eur Arch Otorhinolaryn‐ lung cancer[J]. Cochrane Database Syst Rev，2021，4（4）：
gol，2022，279（9）：4229-4240. CD013257.
[ 6 ] DOHLMAN T H，MCSOLEY M，AMPARO F，et al. [18] LU J，ZHANG W，YU K K，et al. Screening anlotinib
Bevacizumab in high-risk corneal transplantation：a pilot responders via blood-based proteomics in non-small cell
multicenter prospective randomized control trial[J]. Oph‐ lung cancer[J]. FASEB J，2022，36（8）：e22465.
thalmology，2022，129（8）：865-879. [19] GARCIA J，HURWITZ H I，SANDLER A B，et al. Beva‐
[ 7 ] LIN B Y，SONG X M，YANG D W，et al. Anlotinib inhi- cizumab（Avastin®）in cancer treatment：a review of 15
bits angiogenesis via suppressing the activation of VEGFR2， years of clinical experience and future outlook[J]. Cancer
PDGFRβ and FGFR1[J]. Gene，2018，654：77-86. Treat Rev，2020，86：102017.
[ 8 ] 韩宝惠，李凯，周彩存，等. 晚期非小细胞肺癌抗血管生 [20] 杨雳，何杰，任召强，等. 安罗替尼治疗晚期非小细胞肺
成药物治疗中国专家共识（2019 版）[J]. 中国肺癌杂志， 癌效果和安全性的 Meta 分析[J]. 中国医药，2020，15
2019，22（7）：401-412. （4）：545-549.
HAN B H，LI K，ZHOU C C，et al. Chinese expert consen‐ YANG L，HE J，REN Z Q，et al. Efficacy and safety of an‐
sus on antiangiogenic drugs for advanced non-small cell lotinib in treatment of advanced non-small cell lung can‐
lung cancer：2019 edition[J]. Chin J Lung Cancer，2019， cer：a meta analysis[J]. China Med，2020，15（4）：545-549.
22（7）：401-412. [21] SHEN J，HUANG J，HUANG Y，et al. Anlotinib sup‐
[ 9 ] IANNESSI A，BEAUMONT H，LIU Y，et al. RECIST 1.1 presses lung adenocarcinoma growth via inhibiting FASN-
and lesion selection：how to deal with ambiguity at base‐ mediated lipid metabolism[J]. Ann Transl Med，2022，10
line?[J]. Insights Imaging，2021，12（1）：36. （24）：1337.
[10] 刘磊，索婷婷，张彦收，等. 病人在化疗后主观性不良事 [22] HONG C，WEI J P，ZHOU T，et al. FGFR2-ERC1：a sub‐
件评价中的作用[J]. 安徽医药，2020，24（6）：1268-1272， type of FGFR2 oncogenic fusion variant in lung adenocar‐
1277. cinoma and the response to anlotinib[J]. Onco Targets
LIU L，SUO T T，ZHANG Y S，et al. Study on the role of Ther，2022，15：651-657.
patients in subjective adverse events assessment after che‐ [23] RICCARDI C，NAPOLITANO E，PLATELLA C，et al.
motherapy[J]. Anhui Med Pharm J，2020，24（6）：1268- Anti-VEGF DNA-based aptamers in cancer therapeutics
1272，1277. and diagnostics[J]. Med Res Rev，2021，41（1）：464-506.
[11] ROSELL R，CARDONA A F，ARRIETA O，et al. Coregu‐ [24] YANG Y L，CAO Y H. The impact of VEGF on cancer
lation of pathways in lung cancer patients with EGFR mu‐ metastasis and systemic disease[J]. Semin Cancer Biol，
tation：therapeutic opportunities[J]. Br J Cancer，2021，125 2022，86（pt 3）：251-261.
（12）：1602-1611. [25] ZSIROS E，LYNAM S，ATTWOOD K M，et al. Efficacy
[12] KASHIMA Y，SHIBAHARA D，SUZUKI A，et al. Single- and safety of pembrolizumab in combination with bevaci‐
cell analyses reveal diverse mechanisms of resistance to zumab and oral metronomic cyclophosphamide in the
EGFR tyrosine kinase inhibitors in lung cancer[J]. Cancer treatment of recurrent ovarian cancer：a phase 2 nonran‐
Res，2021，81（18）：4835-4848. domized clinical trial[J]. JAMA Oncol，2021，7（1）：78-85.
[13] OHMORI T，YAMAOKA T，ANDO K，et al. Molecular [26] SHI J H，CHENG Y，WANG Q M，et al. Anlotinib as
and clinical features of EGFR-TKI-associated lung injury third- or further-line therapy for short-term relapsed small-
[J]. Int J Mol Sci，2021，22（2）：792. cell lung cancer：subgroup analysis of a randomized phase
[14] KARAMI M，ERIKSEN E，OUWENEEL D M，et al. 2 study（ALTER1202）[J]. Front Med，2022，16（5）：
Long-term 5-year outcome of the randomized IMPRESS 766-772.
in severe shock trial：percutaneous mechanical circulatory （收稿日期：2023-03-05 修回日期：2023-09-21）
support vs. intra-aortic balloon pump in cardiogenic shock （编辑：陈 宏）
after acute myocardial infarction[J]. Eur Heart J Acute

中国药房 2023年第34卷第20期 China Pharmacy 2023 Vol. 34 No. 20 · 2529 ·